Dishman Carbogen Amcis moves up as its arm completes USFDA`s inspection at Switzerland manufacturing site
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Dishman Carbogen Amcis is currently trading at Rs. 103.30, up by 1.90 points or 1.87 % from its previous closing of Rs. 101.40 on the BSE.
The scrip opened at Rs. 101.55 and has touched a high and low of Rs. 104.90 and Rs. 100.65 respectively. So far 78850 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 201.35 on 05-Apr-2022 and a 52 week low of Rs. 80.05 on 03-Feb-2023.
Last one week high and low of the scrip stood at Rs. 105.30 and Rs. 89.75 respectively. The current market cap of the company is Rs. 1619.57 crore.
The promoters holding in the company stood at 59.32%, while Institutions and Non-Institutions held 11.06% and 29.62% respectively.
Dishman Carbogen Amcis’ wholly owned subsidiary--Carbogen Amcis AG has successfully completed a routine U.S. Food and Drug Administration (USFDA) inspection at its manufacturing site in Bubendorf, Switzerland. The inspection was concluded without any major or critical observations.
Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.
